Trevena, Inc. to Participate in March Virtual Investor Conferences
March 01 2021 - 6:00AM
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical
company focused on the development and commercialization of novel
medicines for patients with central nervous system (CNS) disorders,
today announced that management will participate in two upcoming
virtual investor conferences in March. Additional details are
below:
H.C. Wainwright Global Life Sciences Conference
Date: |
|
Tuesday, March 9th |
Format: |
|
One-on-one investor
meetings |
Attendees: |
|
Carrie Bourdow, President
& Chief Executive OfficerBarry Shin, SVP & Chief Financial
OfficerMark A. Demitrack, M.D., SVP & Chief Medical
Officer |
Oppenheimer 31st Annual Healthcare Conference
Date: |
|
Tuesday, March 16th |
Format: |
|
Corporate Presentation &
One-on-one investor meetings |
Time: |
|
3:50 p.m. ET |
Attendees: |
|
Carrie Bourdow, President
& Chief Executive OfficerBarry Shin, SVP & Chief Financial
OfficerMark A. Demitrack, M.D., SVP & Chief Medical
Officer |
Webcast: |
|
https://wsw.com/webcast/oppenheimer9/trvn/2777522 |
A link to the webcast for the Oppenheimer
presentation will be available on the Events page of the Investors
section of the Company’s website at:
https://www.trevena.com/investors/events-presentations/ir-calendar.
A replay of the presentation will be archived on the website and
available for approximately 90 days following the event.
About TrevenaTrevena, Inc. is a
biopharmaceutical company focused on the development and
commercialization of novel medicines for patients with CNS
disorders. The Company has one approved product in the U.S.,
OLINVYK™ (oliceridine) injection, indicated in adults for the
management of acute pain severe enough to require an intravenous
opioid analgesic and for whom alternative treatments are
inadequate. The Company also has four novel and differentiated
investigational drug candidates: TRV250 for the acute treatment of
migraine, TRV734 for maintenance treatment of opioid use disorder,
and TRV027 for acute lung injury / abnormal blood clotting in
COVID-19 patients. The Company has also identified TRV045, a novel
S1P receptor modulator that may offer a new, non-opioid approach to
treating a variety of CNS disorders.
For more information, please visit
www.Trevena.com.
Forward-Looking StatementsAny
statements in this press release about future expectations, plans
and prospects for the Company, including statements about the
Company’s strategy, future operations, clinical development and
trials of its therapeutic candidates, plans for potential future
product candidates, commercialization of approved drug products and
other statements containing the words “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “may,” “might,” “plan,”
“objective,” “predict,” “project,” “suggest,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,”
“ongoing,” or the negative of these terms or similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including: the
commercialization of any approved drug product, the status, timing,
costs, results and interpretation of the Company’s clinical trials
or any future trials of any of the Company’s investigational drug
candidates; the uncertainties inherent in conducting clinical
trials; expectations for regulatory interactions, submissions and
approvals, including the Company’s assessment of the discussions
with the FDA or other regulatory agencies about any and all of its
programs; uncertainties related to the commercialization of
OLINVYK; available funding; uncertainties related to the Company’s
intellectual property; uncertainties related to the ongoing
COVID-19 pandemic, other matters that could affect the availability
or commercial potential of the Company’s therapeutic candidates;
and other factors discussed in the Risk Factors set forth in the
Company’s Annual Report on Form 10-K and Quarterly Reports on Form
10-Q filed with the Securities and Exchange Commission (SEC) and in
other filings the Company makes with the SEC from time to time. In
addition, the forward-looking statements included in this press
release represent the Company’s views only as of the date hereof.
The Company anticipates that subsequent events and developments may
cause the Company’s views to change. However, while the Company may
elect to update these forward-looking statements at some point in
the future, it specifically disclaims any obligation to do so,
except as may be required by law.
Investor Contact:Daniel FerryLifeSci
AdvisorsPhone: 617-430-7576Email: IR@trevena.com
Company Contact:Bob Yoder, SVP and Chief
Commercial OfficerTrevena, Inc.Phone: 610-354-8840
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Apr 2024 to May 2024
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From May 2023 to May 2024